QOL Medical, LLC, a ground-breaking rare disease pharmaceutical company, announced it has selected Optum Frontier Therapies as its new pharmacy partner to support CSID patients nationwide being treated with Sucraid® (sacrosidase) Oral Solution.
Currently, Sucraid® (sacrosidase) Oral Solution is the only treatment for Congenital Sucrase-Isomaltase Deficiency (CSID) in children and adults. Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency. Sucraid® can help improve the breakdown and absorption of sucrose (table sugar) from the intestine and can help relieve the gastrointestinal symptoms of CSID.
“At QOL Medical, we’re passionate about improving the lives of patients living with rare diseases. Our patients and healthcare providers needs are unique.” said Weng Tao, MD, COO of QOL Medical, LLC. “The migration to Optum Frontier Therapies means better care for our patients, and greater attention and support for our healthcare providers.”
Optum Frontier Therapies, a specialty pharmacy and distribution business dedicated to people with rare disease, partners with stakeholders across health care to provide customizable pharmacy and patient services, distribute and dispense specialty medications, and utilize data reporting and analytics to advance therapeutic outcomes and experiences.
“People living with rare disease are often on long and complex journeys, and it is critical to simplify their access to care and expert support,” said Natasha Mayfield, Vice President and General Manager, Optum Frontier Therapies. “As a clinical partner, we are honored to be chosen by QOL Medical to deliver this important therapy to patients living with CSID.”
People with CSID, commonly known as Sucrose (sugar) Intolerance, are unable to properly digest sucrose (table sugar), which is found in foods like ice cream, apples, cake, and corn. In adolescents and adults, CSID has been characterized by symptoms of chronic abdominal pain, gas, bloating, and diarrhea, which overlap with common irritable bowel syndrome (IBS) symptoms. In infants, CSID classically presents as explosive watery diarrhea, failure to thrive, diaper rash, irritability, and acidic stools.